|
US5580856A
(en)
|
1994-07-15 |
1996-12-03 |
Prestrelski; Steven J. |
Formulation of a reconstituted protein, and method and kit for the production thereof
|
|
KR19980703876A
(ko)
|
1995-04-14 |
1998-12-05 |
스티븐 엘. 허스트 |
분산성이 개선된 분말화된 약학적 조성물
|
|
US6685940B2
(en)
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
|
CA2226575C
(en)
|
1995-07-27 |
2011-10-18 |
Genentech, Inc. |
Stabile isotonic lyophilized protein formulation
|
|
IL132240A0
(en)
|
1997-04-07 |
2001-03-19 |
Genentech Inc |
Anti-vegf antibodies
|
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
|
AUPP494798A0
(en)
|
1998-07-29 |
1998-08-20 |
Pacific Biolink Pty Limited |
Protective protein formulation
|
|
US6833349B2
(en)
|
1999-06-08 |
2004-12-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating inflammatory skin diseases
|
|
US7396664B2
(en)
|
1999-06-08 |
2008-07-08 |
Regeneron Pharmaceuticals, Inc. |
VEGF-binding fusion proteins and nucleic acids encoding the same
|
|
US7087411B2
(en)
|
1999-06-08 |
2006-08-08 |
Regeneron Pharmaceuticals, Inc. |
Fusion protein capable of binding VEGF
|
|
US7070959B1
(en)
|
1999-06-08 |
2006-07-04 |
Regeneron Pharmaceuticals, Inc. |
Modified chimeric polypeptides with improved pharmacokinetic properties
|
|
US7303746B2
(en)
|
1999-06-08 |
2007-12-04 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating eye disorders with modified chimeric polypeptides
|
|
MXPA01012630A
(es)
|
1999-06-08 |
2002-07-22 |
Regeneron Pharma |
Polipeptidos quimericos modificados con propiedades farmacocineticas mejoradas.
|
|
US7306799B2
(en)
|
1999-06-08 |
2007-12-11 |
Regeneron Pharmaceuticals, Inc. |
Use of VEGF inhibitors for treatment of eye disorders
|
|
US6586574B1
(en)
|
1999-08-17 |
2003-07-01 |
Nn A/S |
Stabilization of freeze-dried cake
|
|
US8703126B2
(en)
|
2000-10-12 |
2014-04-22 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
|
JP4340062B2
(ja)
|
2000-10-12 |
2009-10-07 |
ジェネンテック・インコーポレーテッド |
粘度の減少した濃縮タンパク質製剤
|
|
AU2002324556A1
(en)
|
2001-07-25 |
2003-02-17 |
Protein Design Labs, Inc. |
Stable lyophilized pharmaceutical formulation of igg antibodies
|
|
AU2002335046A1
(en)
|
2001-10-19 |
2003-05-06 |
Inhale Therapeutic Systems, Inc. |
The use of proton sequestering agents in drug formulations
|
|
US20050123509A1
(en)
|
2001-10-19 |
2005-06-09 |
Lehrman S. R. |
Modulating charge density to produce improvements in the characteristics of spray-dried proteins
|
|
ES2392073T3
(es)
|
2001-11-08 |
2012-12-04 |
Abbott Biotherapeutics Corp. |
Formulación farmacéutica líquida estable de anticuerpos IGG
|
|
SI1478394T1
(sl)
|
2002-02-27 |
2008-12-31 |
Immunex Corp |
STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM
|
|
AU2004229335C1
(en)
|
2003-04-04 |
2010-06-17 |
Genentech, Inc. |
High concentration antibody and protein formulations
|
|
US7399612B2
(en)
|
2003-06-30 |
2008-07-15 |
Regeneron Pharmaceuticals, Inc. |
VEGF-binding fusion proteins and nucleic acids encoding the same
|
|
AR046510A1
(es)
|
2003-07-25 |
2005-12-14 |
Regeneron Pharma |
Composicion de un antagonista de vegf y un agente anti-proliferativo
|
|
US20050112061A1
(en)
|
2003-08-06 |
2005-05-26 |
Jocelyn Holash |
Use of a VEGF antagonist in combination with radiation therapy
|
|
US20050196340A1
(en)
|
2003-08-06 |
2005-09-08 |
Jocelyn Holash |
Use of a VEGF antagonist in combination with radiation therapy
|
|
NZ592039A
(en)
|
2003-08-27 |
2013-03-28 |
Ophthotech Corp |
Combination therapy for the treatment of ocular neovascular disorders
|
|
PL1767546T3
(pl)
|
2004-06-08 |
2012-07-31 |
Chengdu Kanghong Biotechnologies Co Ltd |
Hamujące angiogenezę białka chimeryczne i ich zastosowanie
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
EP1802334B1
(en)
|
2004-10-21 |
2012-08-29 |
Genentech, Inc. |
Method for treating intraocular neovascular diseases
|
|
HUE034109T2
(en)
|
2005-03-25 |
2018-01-29 |
Regeneron Pharma |
VEGF antagonist formulations
|
|
WO2006138181A2
(en)
|
2005-06-14 |
2006-12-28 |
Amgen Inc. |
Self-buffering protein formulations
|
|
EP2377554A1
(en)
|
2005-07-22 |
2011-10-19 |
Amgen, Inc |
Concentrated protein lyophilates, methods and uses
|
|
AU2006272714A1
(en)
|
2005-07-25 |
2007-02-01 |
Trubion Pharmaceuticals, Inc. |
Compositions and methods for protein deaggregation
|
|
KR20080071192A
(ko)
|
2005-11-22 |
2008-08-01 |
와이어쓰 |
면역글로불린 융합 단백질 제형
|
|
JP5405122B2
(ja)
|
2005-12-21 |
2014-02-05 |
ワイス・エルエルシー |
低粘度のタンパク質製剤およびその用途
|
|
FR2895258B1
(fr)
|
2005-12-22 |
2008-03-21 |
Aventis Pharma Sa |
Combinaison comprenant de la combretastatine et des agents anticancereux
|
|
JP2009525986A
(ja)
|
2006-02-03 |
2009-07-16 |
メディミューン，エルエルシー |
タンパク質製剤
|
|
TW200806317A
(en)
|
2006-03-20 |
2008-02-01 |
Wyeth Corp |
Methods for reducing protein aggregation
|
|
US8216575B2
(en)
|
2006-03-31 |
2012-07-10 |
Chengdu Kanghong Biotechnologies Co., Ltd. |
Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
|
|
CN100502945C
(zh)
|
2006-03-31 |
2009-06-24 |
成都康弘生物科技有限公司 |
Vegf受体融合蛋白在治疗眼睛疾病中的应用
|
|
SI2944306T1
(sl)
|
2006-06-16 |
2021-04-30 |
Regeneron Pharmaceuticals, Inc. |
Formulacije antagonista VEGF, primerne za intravitrealno dajanje
|
|
WO2009015345A1
(en)
|
2007-07-25 |
2009-01-29 |
Amgen Inc. |
Pharmaceutical compositions comprising fc fusion proteins
|
|
PE20091174A1
(es)
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
|
ES2968301T3
(es)
|
2008-08-05 |
2024-05-08 |
Wyeth Llc |
Liofilización por encima del colapso
|
|
US8623395B2
(en)
|
2010-01-29 |
2014-01-07 |
Forsight Vision4, Inc. |
Implantable therapeutic device
|
|
WO2010148321A1
(en)
|
2009-06-18 |
2010-12-23 |
Wyeth Llc |
Slow dissolution method for reconstitution of lyophilized material
|
|
CA2764180A1
(en)
|
2009-06-18 |
2010-12-23 |
Wyeth Llc |
Lyophilized formulations for small modular immunopharmaceuticals
|
|
EP2453874A2
(en)
|
2009-07-14 |
2012-05-23 |
Biogen Idec MA Inc. |
Methods for inhibiting yellow color and peroxide formation in a composition
|
|
EP2458990B1
(en)
|
2009-07-28 |
2016-03-30 |
Merck Sharp & Dohme Corp. |
Methods for producing high concentration lyophilized pharmaceutical formulations
|
|
WO2011017330A1
(en)
|
2009-08-04 |
2011-02-10 |
Genentech Inc |
Concentrated polypeptide formulations with reduced viscosity
|
|
US20130029909A1
(en)
|
2009-09-15 |
2013-01-31 |
John Ryan |
Treatment of cancer
|
|
EP3409289B1
(en)
|
2010-02-26 |
2020-09-30 |
Novo Nordisk A/S |
Stable antibody containing compositions
|
|
BR112012022223B1
(pt)
|
2010-03-01 |
2022-08-09 |
Cytodyn Inc |
Formulação de proteína concentrada, uso e método de preparação da mesma
|
|
CN102958538A
(zh)
|
2010-05-03 |
2013-03-06 |
弗·哈夫曼-拉罗切有限公司 |
用于降低含有蛋白质的制剂的粘度的组合物和方法
|
|
MX2012014523A
(es)
|
2010-07-02 |
2013-01-29 |
Genentech Inc |
Tratamiento de desprendimiento epitelial de pigmento vascularizado con terapia anti-vegf.
|
|
WO2012019047A2
(en)
|
2010-08-05 |
2012-02-09 |
Forsight Vision4, Inc. |
Subconjunctival implant for posterior segment drug delivery
|
|
CN103816115B
(zh)
*
|
2010-08-31 |
2017-06-27 |
成都康弘生物科技有限公司 |
一种含有抑制血管增生的融合蛋白的药物组合物及用途
|
|
CN102380096B
(zh)
|
2010-08-31 |
2014-04-30 |
成都康弘生物科技有限公司 |
一种含有抑制血管增生的融合蛋白的药物组合物及用途
|
|
CN103533950A
(zh)
|
2011-01-13 |
2014-01-22 |
瑞泽恩制药公司 |
Vegf拮抗剂在治疗血管生成眼病中的用途
|
|
DK2701773T3
(da)
|
2011-04-25 |
2019-05-20 |
Icon Bioscience Inc |
Dosisstyredele til injektionssprøjte
|
|
JO3283B1
(ar)
|
2011-04-26 |
2018-09-16 |
Sanofi Sa |
تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
|
|
WO2013012022A1
(ja)
|
2011-07-19 |
2013-01-24 |
中外製薬株式会社 |
アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
|
|
WO2013063510A1
(en)
|
2011-10-28 |
2013-05-02 |
Integritybio Inc. |
Protein formulations containing amino acids
|
|
GB201122408D0
(en)
|
2011-12-23 |
2012-02-08 |
Univ Strathclyde |
Method for preparing dry protein formulations
|
|
NZ627859A
(en)
|
2012-01-23 |
2015-09-25 |
Regeneron Pharma |
Stabilized formulations containing anti-ang2 antibodies
|
|
TWI775096B
(zh)
|
2012-05-15 |
2022-08-21 |
澳大利亞商艾佛蘭屈澳洲私營有限公司 |
使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
|
|
PT3858405T
(pt)
|
2012-06-01 |
2023-06-26 |
Novartis Ag |
Seringa
|
|
US20130323242A1
(en)
|
2012-06-01 |
2013-12-05 |
Ophthotech Corp. |
Compositions comprising an anti-pdgf aptamer and a vegf antagonist
|
|
EA201492289A1
(ru)
|
2012-06-01 |
2015-05-29 |
Офтотек Корпорейшн |
Композиции, содержащие аптамер против pdgf и антагонист vegf
|
|
US20150150982A1
(en)
|
2012-06-12 |
2015-06-04 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical formulation for a therapeutic antibody
|
|
DE202013000688U1
(de)
|
2012-07-03 |
2013-03-05 |
Novartis Ag |
Glas-Spritze
|
|
US9592297B2
(en)
|
2012-08-31 |
2017-03-14 |
Bayer Healthcare Llc |
Antibody and protein formulations
|
|
KR102467714B1
(ko)
|
2012-11-08 |
2022-11-16 |
클리어사이드 바이오메디컬, 인코포레이드 |
인간 대상체에서 안구 질병을 치료하기 위한 방법 및 장치
|
|
US9474803B2
(en)
|
2012-11-27 |
2016-10-25 |
Alteogen Inc. |
Composition for stabilizing fusion protein in which protein and FC domain are fused
|
|
EP2956468B1
(en)
|
2013-02-12 |
2020-06-10 |
Bristol-Myers Squibb Company |
Tangential flow filtration based protein refolding methods
|
|
US10274503B2
(en)
|
2013-05-08 |
2019-04-30 |
Vegenics Pty Limited |
Methods of using VEGF-C biomarkers for age-related macular degeneration (AMD) diagnosis
|
|
EP3003369A4
(en)
|
2013-05-28 |
2017-04-26 |
Momenta Pharmaceuticals, Inc. |
Pharmaceutical compositions comprising pyrophosphate
|
|
KR102465025B1
(ko)
|
2013-07-18 |
2022-11-09 |
맨카인드 코포레이션 |
열-안정성 건조 분말 약제학적 조성물 및 방법
|
|
EP3628324A1
(en)
|
2013-11-05 |
2020-04-01 |
Allergan, Inc. |
Method of treating conditions of the eye with an anti-vegf darpin
|
|
RU2702748C2
(ru)
|
2014-05-12 |
2019-10-11 |
Формикон Аг |
Предварительно заполненный пластиковый шприц, содержащий антагонист vegf
|
|
US10478498B2
(en)
|
2014-06-20 |
2019-11-19 |
Reform Biologics, Llc |
Excipient compounds for biopolymer formulations
|
|
CA2952609A1
(en)
|
2014-06-26 |
2015-12-30 |
Amgen Inc. |
Solid protein formulations comprising stabilizer, sugar alcohol, sugar and surfactant
|
|
WO2016008975A1
(en)
|
2014-07-18 |
2016-01-21 |
Sanofi |
Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
|
|
CN105435222B
(zh)
|
2014-09-25 |
2018-05-29 |
信达生物制药(苏州)有限公司 |
重组融合蛋白制剂
|
|
CN104940926B
(zh)
|
2014-09-25 |
2017-09-22 |
信达生物制药(苏州)有限公司 |
重组融合蛋白制剂
|
|
TWI738632B
(zh)
|
2014-11-07 |
2021-09-11 |
瑞士商諾華公司 |
穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
|
|
US20160144025A1
(en)
|
2014-11-25 |
2016-05-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and formulations for treating vascular eye diseases
|
|
HUE057653T2
(hu)
|
2014-12-11 |
2022-05-28 |
Bayer Healthcare Llc |
Kis aktív choroidális neurovaszkularizáció lézióval jellemzett idõskori makuladegeneráció kezelése
|
|
BR112017020948A2
(pt)
*
|
2015-03-31 |
2018-07-10 |
Ildong Pharm Co., Ltd. |
composição farmacêutica, método para preparar um agente, método para tratar uma doença ocular e uso de uma proteína de fusão
|
|
RU2766890C2
(ru)
|
2015-06-16 |
2022-03-16 |
Мерк Патент Гмбх |
Комбинированные способы лечения антагонистами pd-l1
|
|
KR101808234B1
(ko)
*
|
2015-06-23 |
2017-12-12 |
(주)알테오젠 |
IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제
|
|
MX2018000869A
(es)
|
2015-07-22 |
2018-07-06 |
Iconic Therapeutics Inc |
Metodos para tratar trastornos asociados con la angiogenesis y la neovascularizacion.
|
|
AU2016329034B2
(en)
|
2015-09-22 |
2019-05-23 |
Pfizer Inc. |
Method of preparing a therapeutic protein formulation and antibody formulation produced by such a method
|
|
JP6959912B2
(ja)
|
2015-09-23 |
2021-11-05 |
ジェネンテック， インコーポレイテッド |
抗ｖｅｇｆ抗体の最適化変異体
|
|
CA3001346A1
(en)
|
2015-10-16 |
2017-04-20 |
Regeneron Pharmaceuticals, Inc. |
Stable protein compositions
|
|
HK1257422A1
(zh)
|
2015-10-30 |
2019-10-18 |
豪夫迈‧罗氏有限公司 |
抗-因子d抗体变体缀合物及其用途
|
|
RU2734958C2
(ru)
|
2015-11-18 |
2020-10-26 |
Формикон Аг |
Предварительно заполненная фармацевтическая упаковка, содержащая жидкий состав на основе антагониста vegf
|
|
WO2017085253A1
(en)
|
2015-11-18 |
2017-05-26 |
Formycon Ag |
Pre-filled plastic syringe containing a vegf antagonist
|
|
EP3383435A4
(en)
|
2015-11-30 |
2019-07-10 |
Medimmune, LLC |
OPTIMIZED RATES OF AMINO ACIDS AND SUGARS AS AMORPHOUS STABILIZING COMPOUNDS IN PHARMACEUTICAL COMPOSITIONS HAVING HIGH CONCENTRATIONS IN PROTEIN-BASED THERAPEUTICS
|
|
PT3384049T
(pt)
|
2015-12-03 |
2023-08-18 |
Regeneron Pharma |
Método de associação de variantes genéticas com um resultado clínico em doentes que sofrem de degeneração macular relacionada à idade tratados com anti-vegf
|
|
EP3400014A1
(en)
|
2016-01-08 |
2018-11-14 |
Clearside Biomedical, Inc. |
Methods and devices for treating posterior ocular disorderswith aflibercept and other biologics
|
|
ES2824574T3
(es)
|
2016-01-25 |
2021-05-12 |
Sanofi Sa |
Método de predicción del resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cáncer midiendo el nivel de un biomarcador de plasma
|
|
WO2017129685A1
(en)
*
|
2016-01-26 |
2017-08-03 |
Formycon Ag |
Liquid formulation of a vegf antagonist
|
|
EP3443346B1
(en)
|
2016-04-13 |
2023-08-30 |
Medimmune, LLC |
Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
|
|
SI3471780T1
(sl)
|
2016-06-16 |
2021-03-31 |
Adverum Biotechnologies, Inc. |
Zdravljenje SDM-ja z uporabo različice AAV2 z afliberceptom
|
|
CA3030422C
(en)
|
2016-07-13 |
2021-10-26 |
Reform Biologics, Llc |
Stabilizing excipients for therapeutic protein formulations
|
|
SG11201901081XA
(en)
|
2016-08-17 |
2019-03-28 |
Boehringer Ingelheim Int |
Process for the preparation of highly concentrated liquid formulations containing biomolecules
|
|
IL264640B2
(en)
|
2016-08-18 |
2024-03-01 |
Regeneron Pharma |
Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy
|
|
CN109689042B
(zh)
|
2016-08-24 |
2022-07-12 |
北京生命科学研究所 |
用于治疗黄斑变性的与恩他卡朋相关的化合物
|
|
WO2018063963A1
(en)
|
2016-09-28 |
2018-04-05 |
Board Of Regents, The University Of Texas System |
Antibody and protein therapeutic formulations and uses thereof
|
|
IL310367A
(en)
*
|
2016-10-07 |
2024-03-01 |
Regeneron Pharma |
A stable protein at room temperature that has been lyophilized
|
|
CA3043487A1
(en)
|
2016-11-21 |
2018-05-24 |
Just-Evotec Biologics Inc |
Aflibercept formulations and uses thereof
|
|
CN108778336A
(zh)
|
2016-12-01 |
2018-11-09 |
江苏恒瑞医药股份有限公司 |
一种vegfr抑制剂与parp抑制剂联合在制备治疗胃癌的药物中的用途
|
|
US20200368331A1
(en)
|
2016-12-08 |
2020-11-26 |
Gary E. Borodic |
Novel Method of Treating Macular Degeneration Using Botulinum Toxin-Based Pharmaceuticals
|
|
US11123411B2
(en)
|
2016-12-08 |
2021-09-21 |
Gary E. Borodic |
Method of treating macular degeneration using botulinum toxin-based pharmaceuticals
|
|
GEAP202315128A
(en)
|
2016-12-23 |
2023-02-10 |
Serum Institute Of India Pvt Ltd |
Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof
|
|
US10617756B2
(en)
|
2017-01-05 |
2020-04-14 |
Shimojani, LLC |
Drug regimen for treatment of cerebral ischemia
|
|
US10426817B2
(en)
|
2017-01-24 |
2019-10-01 |
Macregen, Inc. |
Treatment of age-related macular degeneration and other eye diseases with apolipoprotein mimetics
|
|
KR101861163B1
(ko)
|
2017-04-26 |
2018-05-25 |
삼천당제약주식회사 |
안과용 약학 조성물
|
|
WO2018201007A2
(en)
|
2017-04-27 |
2018-11-01 |
The Johns Hopkins University |
Dendrimer compositions for use in angiography
|
|
WO2018211517A1
(en)
|
2017-05-16 |
2018-11-22 |
Bhami's Research Laboratory, Pvt. Ltd. |
High concentration protein formulations with reduced viscosity
|
|
EP3630043A1
(en)
|
2017-05-24 |
2020-04-08 |
Formycon AG |
Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
|
|
US20200108064A1
(en)
|
2017-06-08 |
2020-04-09 |
Eye Therapies, Llc |
Low-dose brimonidine combinations and uses thereof
|
|
TW201904610A
(zh)
|
2017-06-14 |
2019-02-01 |
德商拜耳製藥公司 |
用於治療新生血管型青光眼之非抗體vegf拮抗劑
|
|
WO2019023392A1
(en)
|
2017-07-25 |
2019-01-31 |
Elektrofi, Inc. |
FORMATION OF PARTICLES COMPRISING AGENTS
|
|
WO2019020777A1
(en)
|
2017-07-26 |
2019-01-31 |
Formycon Ag |
LIQUID FORMULATION OF A VEGF ANTAGONIST
|
|
WO2019036619A1
(en)
|
2017-08-18 |
2019-02-21 |
Reform Biologics, Llc |
STABILIZING EXCIPIENTS FOR FORMULATIONS OF THERAPEUTIC PROTEIN
|
|
IT201700101582A1
(it)
|
2017-09-12 |
2019-03-12 |
Milano Politecnico |
Dispositivo per rilascio intraoculare
|
|
KR20250093620A
(ko)
|
2017-09-15 |
2025-06-24 |
암젠 인크 |
치료 단백질의 동결건조된 약학적 제형을 위한 방법
|
|
EP3684332A1
(en)
|
2017-09-18 |
2020-07-29 |
Amgen Inc. |
Vegfr-fc fusion protein formulations
|
|
JP2020535199A
(ja)
|
2017-09-29 |
2020-12-03 |
ハンミ ファーマシューティカル カンパニー リミテッド |
効力が向上した持続性タンパク質結合体
|
|
US11246846B2
(en)
|
2017-10-23 |
2022-02-15 |
Michael S. Tempesta |
Trisodium citrate compositions having enhanced uptake across digestive mucosa
|
|
WO2019099786A1
(en)
|
2017-11-16 |
2019-05-23 |
Ophthotech Corporation |
A method for treating or preventing idiopathic polypoidal choroidal vasculopathy (ipcv)
|
|
MA50908A
(fr)
|
2017-11-17 |
2020-09-23 |
Amgen Inc |
Formulations de protéines de fusion vegfr-fc
|
|
WO2019099965A1
(en)
|
2017-11-20 |
2019-05-23 |
Just Biotherapeutics, Inc. |
Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
|
|
AU2018375398C1
(en)
|
2017-11-30 |
2026-01-15 |
Regeneron Pharmaceuticals, Inc. |
Use of a VEGF antagonist to treat angiogenic eye disorders
|
|
CN111093706B
(zh)
|
2017-12-06 |
2022-06-21 |
江苏恒瑞医药股份有限公司 |
Parp抑制剂用于治疗化疗耐药的卵巢癌或乳腺癌的用途
|
|
EP3730126B1
(en)
|
2017-12-22 |
2025-05-14 |
Samsung Bioepis Co., Ltd. |
Liquid composition comprising vegf antagonist
|
|
US11524053B2
(en)
|
2018-01-26 |
2022-12-13 |
The Regents Of The University Of California |
Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
|
|
US11426446B2
(en)
|
2018-03-08 |
2022-08-30 |
Coherus Biosciences, Inc. |
Stable aqueous formulations of aflibercept
|
|
WO2019173767A1
(en)
|
2018-03-08 |
2019-09-12 |
Coherus Biosciences Inc. |
Stable aqueous formulations of aflibercept
|
|
MA52204A
(fr)
|
2018-04-12 |
2021-02-17 |
Amgen Inc |
Procédés de préparation de compositions protéiques stables
|
|
US20210379012A1
(en)
|
2018-04-30 |
2021-12-09 |
Indiana University Research And Technology Corporation |
Antiangiogenic chromane derivative and uses thereof
|
|
CN108671229B
(zh)
|
2018-05-08 |
2022-03-25 |
华博生物医药技术（上海）有限公司 |
一种重组人血管内皮生长因子受体-抗体融合蛋白的药物组合制剂
|
|
JP7235770B2
(ja)
|
2018-05-10 |
2023-03-08 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
高濃度ｖｅｇｆ受容体融合タンパク質を含む製剤
|
|
US11519020B2
(en)
|
2018-05-25 |
2022-12-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
|
|
TW202011995A
(zh)
|
2018-07-03 |
2020-04-01 |
比利時商葛萊伯格有限公司 |
高濃度液體抗體配製物
|
|
EP3851096A4
(en)
|
2018-09-10 |
2022-07-06 |
Samsung Bioepis Co., Ltd. |
LIQUID COMPOSITION WITH PROTEIN
|
|
EP3636657A1
(en)
|
2018-10-08 |
2020-04-15 |
Ablynx N.V. |
Chromatography-free antibody purification method
|
|
WO2020087003A1
(en)
|
2018-10-26 |
2020-04-30 |
Amgen Inc. |
Formulations comprising a tris buffer and a protein
|
|
CN110664757B
(zh)
|
2018-11-19 |
2022-08-02 |
成都瑞沐生物医药科技有限公司 |
纳米晶滴眼剂、其制备方法及其应用
|
|
WO2020106948A1
(en)
|
2018-11-21 |
2020-05-28 |
Regeneron Pharmaceuticals, Inc. |
High concentration protein formulation
|
|
EP3897595B1
(fr)
|
2018-12-20 |
2023-03-15 |
Laboratoires THEA |
Composition ophtalmique nutraceutique pour le traitement de pathologies retiniennes a composante neovasculaire
|
|
US20220098279A1
(en)
|
2019-01-30 |
2022-03-31 |
Amgen Inc. |
Aflibercept attributes and methods of characterizing and modifying thereof
|
|
WO2020167848A1
(en)
|
2019-02-11 |
2020-08-20 |
Surrozen, Inc. |
Modulation of wnt signalling in ocular disorders
|
|
EP3923907B1
(en)
|
2019-02-13 |
2024-09-25 |
Novaliq GmbH |
Compositions and methods for the treatment of ocular neovascularization
|
|
US20200390725A1
(en)
|
2019-06-17 |
2020-12-17 |
Sol-Gel Technologies Ltd. |
Treatment of ocular diseases with ophthalmic tapinarof compositions
|
|
WO2020255135A1
(en)
|
2019-06-17 |
2020-12-24 |
Sol-Gel Technologies Ltd. |
Treatment of ocular inflammatory diseases with topical ophthalmic tapinarof compositions
|
|
US20200390724A1
(en)
|
2019-06-17 |
2020-12-17 |
Sol-Gel Technologies Ltd. |
Treatment of ocular diseases with ophthalmic tapinarof compositions
|
|
CN112203642B
(zh)
|
2019-03-25 |
2025-03-07 |
阿特根公司 |
用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物
|
|
AU2020254582B2
(en)
|
2019-04-01 |
2025-12-18 |
Genentech, Inc. |
Compositions and methods for stabilizing protein-containing formulations
|
|
CA3134538A1
(en)
|
2019-04-03 |
2020-10-08 |
Denali Therapeutics Inc. |
Formulations of protein molecules comprising iduronate 2-sulfatase
|
|
US12599669B2
(en)
|
2019-04-23 |
2026-04-14 |
Amgen Inc. |
Use of low molecular weight polyvinylpyrrolidone (PVP) to reduce viscosity of high concentration protein formulations
|
|
EP3736574A1
(en)
|
2019-05-07 |
2020-11-11 |
Atlas Antibodies AB |
A formulation comprising an isotope labeled fusion polypeptide
|
|
WO2020239051A1
(zh)
|
2019-05-30 |
2020-12-03 |
江苏恒瑞医药股份有限公司 |
Cdk4/6抑制剂与vegfr抑制剂联合在制备治疗肿瘤的药物中的用途
|
|
JP2022540148A
(ja)
|
2019-07-10 |
2022-09-14 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
低減したレベルの宿主細胞タンパク質を含む方法および組成物
|
|
MX2022001433A
(es)
|
2019-08-06 |
2022-02-22 |
Hoffmann La Roche |
Tratamiento personalizado de enfermedades oftalmologicas.
|
|
US20210100856A1
(en)
|
2019-09-11 |
2021-04-08 |
Adverum Biotechnologies, Inc. |
Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept
|
|
AU2020345174A1
(en)
|
2019-09-12 |
2022-03-31 |
Lupin Limited |
Modified dosing of VEGF inhibitors for ophthalmic use
|
|
US20220340630A1
(en)
|
2019-09-13 |
2022-10-27 |
National Science And Technology Development Agency |
Composition of renaturation buffer solution for dimeric proteins and method of renaturation dimeric proteins using the composition thereof
|
|
US20220331430A1
(en)
|
2019-09-17 |
2022-10-20 |
Merck Patent Gmbh |
Camphorsulfonic acid and combinations thereof with cationic excipients as viscosity reducing agents in high concentrated protein formulations
|
|
EP4057980A1
(en)
|
2019-11-15 |
2022-09-21 |
F. Hoffmann-La Roche AG |
Prevention of visible particle formation in aqueous protein solutions
|
|
JP2023504821A
(ja)
|
2019-12-03 |
2023-02-07 |
四川弘合生物科技有限公司 |
エレメンを含む医薬組成物、その調製方法、及びその使用
|
|
KR20220110555A
(ko)
|
2019-12-06 |
2022-08-08 |
리제너론 파마슈티칼스 인코포레이티드 |
Vegf 미니-트랩 및 그의 사용 방법
|
|
KR20240007293A
(ko)
|
2019-12-06 |
2024-01-16 |
리제너론 파아마슈티컬스, 인크. |
항-vegf 단백질 조성물 및 이를 생산하는 방법
|
|
KR20210077645A
(ko)
|
2019-12-17 |
2021-06-25 |
주식회사 프로젠 |
신규 주사제 제형
|
|
WO2021146328A1
(en)
|
2020-01-13 |
2021-07-22 |
Aptevo Research And Development Llc |
Formulations for protein therapeutics
|
|
CN115697333A
(zh)
|
2020-02-19 |
2023-02-03 |
科尼尔赛德生物医学公司 |
包含阿西替尼的组合物和治疗眼部疾病的方法
|
|
PT3884929T
(pt)
|
2020-03-25 |
2023-08-09 |
Ocular Therapeutix Inc |
Implante ocular contendo um inibidor da tirosina cinase
|
|
WO2021203769A1
(zh)
|
2020-04-10 |
2021-10-14 |
江苏恒瑞医药股份有限公司 |
一种抗pd-1抗体在制备治疗肢端黑色素瘤的药物中的用途
|
|
EP4138778A1
(en)
|
2020-04-22 |
2023-03-01 |
Dragonfly Therapeutics, Inc. |
Formulation, dosage regimen, and manufacturing process for heterodimeric fc-fused proteins
|
|
CA3180401A1
(en)
|
2020-06-11 |
2021-12-16 |
Bartosz SIKORSKI |
Methods of improving retina-associated disease outcome using ccr3-inhibitors
|
|
US11944663B2
(en)
|
2020-06-18 |
2024-04-02 |
Chengdu Kanghong Biotechnologies Co. Ltd. |
Method for treating angiogenic eye disorders using VEGF antagonists
|
|
CN115803010A
(zh)
|
2020-07-09 |
2023-03-14 |
豪夫迈·罗氏有限公司 |
浓缩的蛋白质组合物、它们的制备及其用途
|
|
WO2022011323A1
(en)
|
2020-07-10 |
2022-01-13 |
Iconic Therapeutics, Inc. |
Ocular disease treatment using anti-tissue factor antibodies
|
|
IL299671A
(en)
|
2020-07-13 |
2023-03-01 |
Merck Patent Gmbh |
Viscosity-reducing excipients and their combinations for high-concentration protein formulations
|
|
US11524998B2
(en)
|
2020-07-16 |
2022-12-13 |
Novartis Ag |
Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
|
|
KR20230047359A
(ko)
|
2020-07-29 |
2023-04-07 |
시아겐 인크. |
트라스투주맙, 탁산 및 vegfr-2 길항제와 병용하여 투카티닙을 이용하는 her2 양성 암의 치료 방법
|
|
KR20220015976A
(ko)
|
2020-07-31 |
2022-02-08 |
(주)셀트리온 |
안정한 약제학적 제제
|
|
DE102020005002A1
(de)
|
2020-08-17 |
2022-02-17 |
Epo Experimentelle Pharmakologie & Onkologie Berlin-Buch Gmbh |
Mittel zur Therapie von Tumorerkrankungen
|
|
WO2022056326A1
(en)
|
2020-09-11 |
2022-03-17 |
Elixir Medical Corporation |
Anticoagulant compounds, methods and devices for ophthalmic use
|
|
MX2023004839A
(es)
|
2020-10-30 |
2023-06-29 |
Eluminex Biosciences Suzhou Ltd |
Inhibidores de factores angiogenicos.
|
|
US20240024416A1
(en)
|
2020-10-30 |
2024-01-25 |
Gemini Therapeutics Sub, Inc. |
Methods for treating inflammatory ocular diseases with complement factor h
|
|
EP4243780A1
(en)
|
2020-11-13 |
2023-09-20 |
AstraZeneca UK Limited |
Pharmaceutical formulation
|
|
US20220151920A1
(en)
|
2020-11-18 |
2022-05-19 |
Bend Research, Inc. |
Inhalable dry powder formulations comprising angiogenesis inhibitors
|
|
FI20215186A1
(en)
|
2021-02-19 |
2022-08-20 |
Rebio Tech Oy |
Compositions for ophthalmic treatment
|
|
CA3213505A1
(en)
|
2021-03-16 |
2022-09-22 |
Kashiv Biosciences, Llc |
Novel formulation of fusion protein
|
|
WO2022201084A1
(en)
|
2021-03-26 |
2022-09-29 |
Novartis Ag |
Methods for treating ocular diseases
|
|
KR20230167100A
(ko)
|
2021-04-09 |
2023-12-07 |
에이버맥스 바이오파마 인크. |
안구 트랜스진 발현을 위한 조성물 및 방법
|
|
BR112023019056A2
(pt)
|
2021-04-27 |
2024-01-16 |
Adverum Biotechnologies Inc |
Métodos para tratar doenças oculares usando variantes de aav2 que codificam aflibercepte
|
|
WO2022229932A1
(en)
|
2021-04-29 |
2022-11-03 |
Einar Stefansson |
Hypoxia inducible factor (hif) inhibitors for treatment of atrophy associated with retinal hypoxia
|
|
PL4185318T3
(pl)
|
2021-05-17 |
2026-01-12 |
Regeneron Pharmaceuticals, Inc. |
Rozszerzone schematy leczenia dużymi dawkami antagonistów vegf w leczeniu angiogennych zaburzeń oka
|
|
WO2023001288A1
(zh)
|
2021-07-23 |
2023-01-26 |
百奥泰生物制药股份有限公司 |
整合素GPIIb/IIIa拮抗剂及其和抗VEGF抗体联合用药的应用
|
|
WO2023023278A2
(en)
|
2021-08-18 |
2023-02-23 |
University Of Utah Research Foundation |
Multigene constructs for treatment of age-related macular degeneration and other complement dysregulation-related conditions
|
|
EP4398877A1
(en)
|
2021-09-06 |
2024-07-17 |
LEK Pharmaceuticals d.d. |
Formulations for vegf receptor fusion proteins
|
|
EP4147709A1
(en)
|
2021-09-14 |
2023-03-15 |
The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth |
A composition comprising il-36 and/or il-18 for use in treating ocular disorders
|
|
US20250009850A1
(en)
|
2021-10-29 |
2025-01-09 |
Alteogen, Inc. |
Pharmaceutical composition comprising human hyaluronidase ph20 and drug
|